What are the stocks you need to know in the vaccine race
has been defined by the outbreak of Covid-19, which according to many health
experts has yet to even reach its peak. To date, a vaccine has not yet been
created to combat the virus, though pharmaceutical companies worldwide are
aggressively pursuing one.
has made investment in pharmaceutical stocks one of the most attractive options
in 2020, given the huge potential upside of rolling out the first vaccine for
EuropeFX is clearly cognizant of this demand, having recently
expanded its own offering to include a basket of Pharma Stocks. The brokerage is now offering exposure into seven different
pharmaceutical companies that are currently the frontrunners for a Covid-19
Why now could be an interesting time to
invest in Pharma Stocks
of thousands have died worldwide and the demand for a vaccine has never been
higher. This has created an unprecedented demand, which could catapult a pharmaceutical’s
valuation through the roof overnight.
pharmaceutical companies face long roads to inventing vaccines. Long before these
get to the market, a vaccine has to pass multiple stages of trials to ensure
its safety. These are decreased however once the World Health Organization (WHO)
has announced a pandemic, which is the case for Covid-19.
As a result,
several pharmaceutical companies have seen an extraordinary level of speculative
interest from investors during the trial stages of a vaccine.
Which companies could you invest in?
now has on offer the seven pharmaceutical companies leading the race for a
Covid-19 vaccine globally. This includes the following companies:
Gilead Sciences Inc.
A research-based biopharmaceutical
company, Gilead Sciences, currently carries over twenty-five marketed
treatments in the United States for HIV and Aids, Liver Diseases, Hematology
and Oncology, Cardiovascular Disease and Inflammation and Respiratory Disease.
Gilead is currently in Phase-3 trials for Remdesivir, a Covid-19 drug.
in Darmstadt, Germany, Merck & Co is active in 66 countries and with around
57,000 employees, the Company generated sales of €16.2 billion in 2019. The
Company is active in all areas of pharmaceutical production and food safety and
is heavily involved in the performance material sector for a broad and diverse
range of industries.
Founded in the United States in
1980, Amgen has grown to be one of the world’s leading independent
biotechnology companies. Amgen is currently focused on six therapeutic areas:
cardiovascular disease, oncology, bone health, neuroscience, nephrology, and
inflammation, the Company generated sales of $22.2 billion in 2019.
Dynavax Technologies Inc.
Technologies Corporation develops and commercializes novel vaccines.
Company’s first commercial product, HEPLISAV-B [Hepatitis B Vaccine
(Recombinant), Adjuvanted], a hepatitis B vaccine for adults, is approved in
the United States. 2019 saw product revenue of $34.6 million.
in Geneva, Switzerland, Biogen helped pioneer the biotechnology industry. A
leader in the development of treatments for Multiple Sclerosis, Spinal Muscular
Atrophy, and Alzheimer’s Disease, Biogen’s revenues in 2019 were over $14.3
billion, for a 4.5% increase in total revenues year over year.
Founded in Germany, Biotest markets
different products in three therapeutic areas: clinical immunology, hematology,
and intensive care medicine. The Company is active globally, with locations in
Europe, South America, and the Russian Federation. 2019 saw revenues of over
€419 million, and the Company embarked on an ambitious expansion program with
investments of over €300 million planned for their Dreieich location with the
creation of over 300 new jobs in the region.
Inc., a clinical stage biotechnology company, develops therapeutics and
vaccines based on messenger RNA for the treatment of infectious diseases,
immuno-oncology, rare diseases, and cardiovascular diseases.
a global leader in Forex, CFDs, stocks, commodities, cryptocurrencies, and
more. The company utilizes STP trade execution, offering live webinars and
education sessions and an extensive lineup of tradable assets, markets,
platforms and trading options.
Risk Warning: CFDs are complex instruments and carry a high risk of losing money
quickly due to leverage. 78.94% of retail investor accounts lose money
when trading CFDs with this provider. The information contained in
this market overview should in no way be construed as investment advice and/or
as a proposal and/or request for trading activities and financial transactions. The data contained in this market overview is
not necessarily real-time or error-free.
The data and prices on the material are not necessarily provided by a
market or exchange, but by market makers, so that prices may not be accurate
and may differ from the actual price in a particular market, meaning that
prices are indicative and not suitable for trading purposes. There is no guarantee and/or prediction of
future performance. EuropeFX, its
affiliates, agents, directors or employees do not guarantee the accuracy or
validity of any information or data provided and shall not be liable for any
loss arising from any investment based thereon.
Trading Forex/CFD’s carries a high level of risk and may result in the
loss of your entire investment.
Forex/CFD’s are leveraged products and therefore trading Forex/CFD’s may
not be suitable for all investors. It is
recommended not to invest more money than you can afford to lose in order to
avoid significant financial problems in case of losses. Please make sure that you define the maximum
risk for yourself.